Daniela Gordillo-Bastidas, Edén Oceguera-Contreras, Adriana Salazar-Montes, Jaime González-Cuevas, Luis Daniel Hernández-Ortega, Juan Armendáriz-Borunda, Institute of Molecular Biology in Medicine and Gene Therapy/CUCS, University of Guadalajara, Guadalajara, Jalisco 44100, México.
World J Gastroenterol. 2013 Dec 21;19(47):9020-33. doi: 10.3748/wjg.v19.i47.9020.
To determine the molecular mechanisms involved in experimental hepatic fibrosis prevention by caffeine (CFA).
Liver fibrosis was induced in Wistar rats by intraperitoneal thioacetamide or bile duct ligation and they were concomitantly treated with CFA (15 mg/kg per day). Fibrosis and inflammatory cell infiltrate were evaluated and classified by Knodell index. Inflammatory infiltrate was quantified by immunohistochemistry (anti-CD11b). Gene expression was analyzed by quantitative reverse transcription-polymerase chain reaction for collagen I (Col-1), connective tissue growth factor (CTGF), transforming growth factor β1 (TGF-β1), tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), IL-6, superoxide dismutase (SOD) and catalase (CAT). Activation of Nrf2 and Snail-1 was analyzed by Western-blot. TNF-α expression was proved by enzyme-linked immunosorbant assay, CAT activity was performed by zymography.
CFA treatment diminished fibrosis index in treated animals. The Knodell index showed both lower fibrosis and necroinflammation. Expression of profibrogenic genes CTGF, Col-1 and TGF-β1 and proinflammatory genes TNF-α, IL-6 and IL-1 was substantially diminished with CFA treatment with less CD11b positive areas. Significantly lower values of transcriptional factor Snail-1 were detected in CFA treated rats compared with cirrhotic rats without treatment; in contrast Nrf2 was increased in the presence of CFA. Expression of SOD and CAT was greater in animals treated with CFA showing a strong correlation between mRNA expression and enzyme activity.
Our results suggest that CFA inhibits the transcriptional factor Snail-1, down-regulating profibrogenic genes, and activates Nrf2 inducing antioxidant enzymes system, preventing inflammation and fibrosis.
确定咖啡因(CFA)预防实验性肝纤维化的分子机制。
通过腹腔注射硫代乙酰胺或胆管结扎诱导 Wistar 大鼠肝纤维化,并同时用 CFA(每天 15mg/kg)治疗。通过 Knodell 指数评估和分类纤维化和炎症细胞浸润。通过免疫组织化学(抗 CD11b)定量炎症浸润。通过定量逆转录聚合酶链反应分析胶原 I(Col-1)、结缔组织生长因子(CTGF)、转化生长因子β1(TGF-β1)、肿瘤坏死因子α(TNF-α)、白细胞介素-1(IL-1)、IL-6、超氧化物歧化酶(SOD)和过氧化氢酶(CAT)的基因表达。通过 Western-blot 分析 Nrf2 和 Snail-1 的激活。通过酶联免疫吸附试验证明 TNF-α表达,通过同工酶法测定 CAT 活性。
CFA 治疗降低了治疗动物的纤维化指数。Knodell 指数显示纤维化和坏死性炎症均较低。CFA 治疗后,促纤维化基因 CTGF、Col-1 和 TGF-β1 以及促炎基因 TNF-α、IL-6 和 IL-1 的表达明显减少,CD11b 阳性区域减少。与未治疗的肝硬化大鼠相比,CFA 治疗大鼠的转录因子 Snail-1 表达明显降低;相反,CFA 存在时 Nrf2 增加。CFA 治疗的动物中 SOD 和 CAT 的表达更高,mRNA 表达与酶活性之间存在很强的相关性。
我们的结果表明,CFA 抑制转录因子 Snail-1,下调促纤维化基因,并激活 Nrf2 诱导抗氧化酶系统,从而预防炎症和纤维化。